{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-23-000247","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2023-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.962808+00:00","generated_at":"2026-06-20T03:52:04.137338+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"vTv Therapeutics appoints Elizabeth Keiley as EVP and General Counsel","bullets":["Elizabeth Keiley appointed Executive Vice President and General Counsel, effective immediately.","Keiley brings legal experience from Entasis Therapeutics, Oxford Immunotec, and Zimmer.","She will support vTv's capital funding goals and upcoming Phase 3 trials for TTP399.","vTv is a clinical-stage biopharma focused on oral treatments for type 1 diabetes and cystic fibrosis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-23-000247","json":"https://secwatch.observer/filing/0000950142-23-000247.json","markdown":"https://secwatch.observer/filing/0000950142-23-000247.md","text":"https://secwatch.observer/filing/0000950142-23-000247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000095014223000247/0000950142-23-000247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000095014223000247/eh230326253_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T03:52:04.137338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}